Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Increasing incidence and changing trends in etiology & survival rates in HCC in a European cohort.

JHEP reports : innovation in hepatology·2026
Same author

Validated Early Detection Metrics Reduce the Population Requiring Liver Fibrosis Screening.

Gastroenterology·2026
Same author

Assessing Europe's policy readiness to confront the MASLD/MASH public health threat.

The Lancet regional health. Europe·2026
Same author

Metabolic Liver Disease Beyond the Liver: Association of Metabolic Dysfunction-Associated Steatotic Liver Disease with Cardiovascular and Renal Diseases.

Clinics in liver disease·2026
Same author

Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Combination of quantitative MRI and laboratory markers for the detection and staging of metabolic dysfunction-associated steatotic liver disease.

European radiology·2026

相关实验视频

Updated: May 23, 2026

A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium
11:00

A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium

Published on: June 23, 2010

受损的LCAT功能与动脉样硬化增加有关.

G Kees Hovingh1, Barbara A Hutten, Adriaan G Holleboom

  • 1Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.

Circulation
|August 3, 2005
PubMed
概括
此摘要是机器生成的。

患有LCAT基因缺陷的人具有较低的HDL胆固醇和高的甘油三,增加心血管疾病的风险. 针对LCAT可能为心血管疾病预防提供一个新的策略.

更多相关视频

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus
06:43

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Published on: December 8, 2013

Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

相关实验视频

Last Updated: May 23, 2026

A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium
11:00

A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium

Published on: June 23, 2010

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus
06:43

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Published on: December 8, 2013

Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

科学领域:

  • 生物化学 生物化学
  • 遗传学 是一个遗传学.
  • 心血管医学 心血管医学

背景情况:

  • 低HDL胆固醇是心血管疾病 (CVD) 的已知危险因素.
  • 由于莱西丁:胆固醇酸转移酶 (LCAT) 基因突变,严重降低的HDL胆固醇在心血管疾病风险中的作用仍然不清楚.
  • 了解LCAT突变载体中心血管疾病风险可能会揭示LCAT作为治疗点.

研究的目的:

  • 调查LCAT基因突变与心血管风险因素之间的关联.
  • 在LCAT基因缺陷的个体中评估心血管风险标志物.

主要方法:

  • 评估了脂质,脂蛋白,C反应蛋白 (CRP) 和心动脉内心介质厚度 (IMT).
  • 对比47个LCAT基因突变的异构体与58个家族对照.
  • 根据年龄,性别和酒精使用情况调整后的统计分析.

主要成果:

  • 异类动物的HDL胆固醇降低了36%,甘油三脂增加了23%,CRP增加了2.1倍.
  • 与对照人群相比,异构卵性体内 Carotid IMT 显著增加 (P<0.0015 经调整后).

结论:

  • LCAT基因缺陷与较低的HDL胆固醇,高甘油和增加的CRP有关.
  • 观察到IMT的增加表明LCAT可以防止动脉样硬化.
  • 针对LCAT增加HDL胆固醇可能是降低心血管疾病风险的可行策略.